Popular Articles

U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial In Trauma Patients Remains On FDA Hold
Biopure Corporation (Nasdaq: BPUR) announced that the Food and Drug Administration has advised the U.S. Naval Medical Research Center (NMRC) by letter that it may not initiate a clinical trial of Biopure"s oxygen therapeutic Hemopure(R) [hemoglobin glutamer -- 250 (bovine)] under a proposed protocol submitted to the FDA in March 2009. As previously announced, the study, "Restore Effective Survival in Shock" (RESUS) was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission, including the most recent, was placed on clinical hold.

Good Bet In Market Pullback: Health-Care Shares
"As sentiment and the stock market increasingly look bearish, look for the recent outperformance in health care to continue," The Wall Street Journal reports. Health-care firms were "hardly a leader" during the "initial run of stocks following the March lows," but they also "fared much better during the market"s plummet. Last week, "health care was the one exception to a sliding market." Katie Stockton, chief market technician for MKM Partners, "says it is likely most of the health-care sector will outperform and not just large pharmaceutical companies" (Rogow, 6/23).
News of the day
Better Diagnosis Of Diarrhea-Causing Bacteria: New Method Developed By Researchers From Helmholtz Center For Infection Research, Germany
It is based on detecting short, repetitive DNA segments in the genome of bacteria. Every single bacterial strain has such characteristic repeats. "With this method we are able to identify bacterial strains as well as clarify their genetic relationships. Furthermore, we can show how new pathogenic variants develop," says Manfred Hç¶fle, researcher at the HZI. The results have now been published in the current issue of the scientific journal Applied and Environmental Microbiology. The work is part of the two European Union funded projects "Healthy Water" and "AQUA-chip". Manfred Hç¶fle is coordinator of both projects that deal with various aspects of the microbiological safety of both, drinking water and sea water.
Public Health

Team Uncovers The Molecular Basis For The Regulation Of Blood Clotting

By applying cutting-edge techniques in single-molecule manipulation, researchers at Harvard University have uncovered a fundamental feedback mechanism that the body uses to regulate the clotting of blood. The finding, which could lead to a new physical, quantitative, and predictive model of how the body works to respond to injury, has implications for the treatment of bleeding disorders. A team, co-led by Timothy A. Springer, Latham Family Professor of Pathology at Harvard Medical School and Children"s Hospital Boston, and Wesley P. Wong, Rowland Junior Fellow and a Principal Investigator at the Rowland Institute at Harvard, reported its discovery about the molecular basis for the feedback loop responsible for hemostasis in the June 5th issue of Science. "The human body has an incredible ability to heal from life"s scrapes and bruises," explains Wong. "A central aspect of this response to damage is the ability to bring bleeding to end, a process known as hemostasis. Yet regulating hemostasis is a complex balancing act." Too much hemostatic activity can lead to an excess of blood clots, resulting in a potentially deadly condition known as thrombosis. If too little hemostatic activity occurs in the body, a person may bleed to death. To achieve the proper balance, the body relies on a largely mechanical feedback system that relies on the miniscule forces applied by the circulation system on a molecular "force sensor" known as the A2 domain of the blood clotting protein von Willebrand factor (VWF). By manipulating single molecules of this A2 domain, the researchers found that the A2 domain acts as a highly sensitive force sensor, responding to very weak tensile forces by unfolding, and losing much of its complex three-dimensional organization. This unfolding event allows the cutting of the molecule by an enzyme known as ADAMTS13. "In the body, these cutting events decrease hemostatic potential and also enable blood clots to be trimmed in size. The system is so finely tuned that the A2 shear sensor is able to regulate the size of VWF within the blood stream, maintaining the optimal size for responding properly to traumas," says Wong. To make the discovery, the team relied upon an "optical tweezers" system developed in Wong"s lab. The tweezers are capable of applying miniscule forces to individual molecules while observing nanoscale changes in their length. Such manipulations enabled the researchers to characterize both the unfolding and refolding rates of single A2 molecules under force, as well as their interaction with the enzyme. The molecular construct was created in Dr. Springer"s lab, and consisted of an A2 domain connected to two DNA handles for manipulation. This elegant molecular system allowed the VWF "shear sensor" to be carefully studied and tested in isolation. Ultimately, this work enhances the understanding of how the body is able to regulate the formation of blood clots, and is step towards a physical, quantitative, and predictive model of how the body responds to injury. It also gives insight into how bleeding disorders, such as type 2A von Willebrand disease, disrupt this regulation system, potentially leading to new avenues for treatment and diagnosis. Notes: Wong and Springer"s co-authors include Xiaohui Zhang, Kenneth Halvorsen, and Cheng-Zhong Zhang. The authors acknowledge the support of the National Institutes of Health, the American Heart Association, and the Rowland Junior Fellows program. Michael Patrick Rutter Harvard University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):